An end to thyroid-related eye bulging?
Phoebe Harkin | | Quick Read
Thyroid eye disease is rare, but its effects are significant. The condition is associated with outward bulging of the eye and can cause eye pain, double vision, and light sensitivity, which can be severe enough to affect daily activities. But there is hope. Teprotumumab has become the first FDA-approved medicine for thyroid eye disease after a study found that it improves eye bulging, regardless of patient gender, age, or smoking status.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine